Uncategorized
Beyond The Numbers: 7 Analysts Discuss Terex Stock
Latest Ratings for TEX Date Firm Action From To Mar 2022 Wells Fargo Initiates Coverage On Overweight Feb 2022 JP Morgan Maintains Overweight Dec 2021 Barclays Maintains Equal-Weight View More Analyst Ratings for TEX View the Latest Analyst Ratings read more
Nucor Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Latest Ratings for NUE Date Firm Action From To Feb 2022 Goldman Sachs Maintains Neutral Jan 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Wolfe Research Downgrades Peer Perform Underperform View More Analyst Ratings for NUE View the Latest Analyst Ratings read more
Analyst Expectations For Zebra Technologies’s Future
Latest Ratings for ZBRA Date Firm Action From To Mar 2022 Needham Maintains Buy Feb 2022 Needham Maintains Buy Feb 2022 Needham Maintains Buy View More Analyst Ratings for ZBRA View the Latest Analyst Ratings read more
A Glimpse Into The Expert Outlook On Steel Dynamics Through 9 Analysts
Latest Ratings for STLD Date Firm Action From To Feb 2022 Goldman Sachs Maintains Buy Jan 2022 Wolfe Research Downgrades Peer Perform Underperform Oct 2021 Morgan Stanley Downgrades Overweight Equal-Weight View More Analyst Ratings for STLD View the Latest Analyst Ratings read more
Merck’s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies. read more
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. read more
